Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

UK impact of trial data

Written by | 8 Jul 2019

Dr Fiona McDonald (London, UK) discusses radical treatment for oligo metastatic NSCLC and if it should be the standard of care and Professor James Spicer (London, UK), the session Chair,  gives… read more.

Translational oncology: Tumour mutational burden and exploitation of DNA repair

Written by | 5 Jul 2019

Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.

PACIFIC and beyond – the promise of immunotherapy

Written by | 10 May 2019

Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).

Advanced stage disease

Written by | 5 Dec 2018

As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced… read more.

WCLC 2018: Variety of approaches can work in oligometastatic disease

Written by | 17 Oct 2018

Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.

WCLC 2018: Lung cancer stigma is detrimental to patient care

Written by | 17 Oct 2018

Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients’ care.

WCLC 2018: Importance of QOL outcome measures in clinical trials

Written by | 17 Oct 2018

WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.

WCLC 2018: Accessibility & quality of life: a patient focus at WCLC

Written by | 17 Oct 2018

Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said… read more.

WCLC 2018: PACIFIC: durvalumab results impressive, but not without questions

Written by | 17 Oct 2018

Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the… read more.

WCLC 2018: Early ALTA-1L data encouraging for brigatinib

Written by | 17 Oct 2018

The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with… read more.

WCLC 2018: Success of combined screening and smoking cessation pilots

Written by | 17 Oct 2018

Professor Gail Darling (WCLC co-President, Toronto, Canada) discusses the success of combined screening and smoking cessation pilot in Ontario.

WCLC 2018: Do we have a UK-wide screening programme that is ready to implement?

Written by | 17 Oct 2018

Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) and Professor David Baldwin (Nottingham, UK) detail current UK pilots and a screening protocol that is currently going through the NHS England… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.